Potential utility of reverse-phase protein array for refining precision cancer medicine

Rapid advances in next-generation sequencing (NGS) technology over the past decade have led to a paradigm shift cancer treatment from one-size-fits-all medicine genomics-based precision that has become more accessible general clinical practice. It, however, helped only less than 10% of patients who taken genomic profiling tests. Proteomics-based rather approaches can capture biological processes directly contributing pathogenesis. There is, therefore, growing need for simultaneous proteomic analysis next stage medicine. In future, it is expected data genomic, transcriptomic, proteomic, and epigenomic analyses will be integrated complemented accurately understand disease states propose therapeutic strategies. Reverse-phase protein array (RPPA) enables semi-quantitative, accurate, high throughput signal even small amounts samples. This review introduces its current status application medicine, highlights potential utility RPPA improving